{"id":1924,"date":"2021-01-06T14:50:48","date_gmt":"2021-01-06T09:05:48","guid":{"rendered":"https:\/\/medicosnext.com\/?p=1924"},"modified":"2021-01-06T14:50:48","modified_gmt":"2021-01-06T09:05:48","slug":"covid-19-vaccine-development","status":"publish","type":"post","link":"https:\/\/medicosnext.com\/?p=1924","title":{"rendered":"COVID-19 VACCINE DEVELOPMENT"},"content":{"rendered":"

CanSino Biologics\"\"<\/a><\/strong><\/p>\n

CanSino Biologics\u2019 <\/strong>vaccine is a one-dose adenovirus-based vaccine that can be stored at 2\u20138 \u00baC. Its trial included 40,000 volunteers.<\/p>\n

March 2020: <\/strong>China\u2019s CanSino Biologics and the Academy of Military Medical Sciences launch phase 1 trial in Wuhan after getting regulatory approval to start human trials of their vaccine against the novel coronavirus.<\/p>\n

June 29, 2020: <\/strong>Vaccine approved for military use in China.<\/p>\n

September 15, 2020: <\/strong>Phase 3 trial begins in a number of countries, including Saudi Arabia, Pakistan, and Russia.<\/p>\n

 <\/p>\n

Pfizer-BioNTech<\/strong><\/p>\n

\"\"<\/p>\n

Pfizer-BioNTech\u2019s <\/strong>vaccine is a two-dose mRNA vaccine that has to be stored at -70 \u00baC. The trial comprised of 44,000 volunteers. The company aims to produce 50 million doses in 2020 and 1.3 billion in 2021. Cost per dose is $19.50.<\/p>\n

April 29, 2020: <\/strong>US company Pfizer and German start-up BioNTech begins trial of their vaccine.<\/p>\n

November 29, 2020<\/strong>: Trial result shows 90% efficacy (later updated to 95%).<\/p>\n

December 2, 2020: <\/strong>UK grants approval for emergency use.<\/p>\n

December 9, 2020: <\/strong>Canada grants approval for emergency use.<\/p>\n

December 11, 2020: <\/strong>US FDA grants emergency use authorization in USA.<\/p>\n

 <\/p>\n

Gamaleya Research Institute<\/strong><\/p>\n

Gamaleya\u2019s vaccine <\/strong>(Sputnik V) is a two-dose adenovirus-based vaccine that can be stored at 2\u22128 \u00baC. Its trial included 40,000 volunteers. Cost is $10 per dose.<\/p>\n

May 2020: <\/strong>Russia\u2019s Gamaleya Research Institute announces development of Sputnik V vaccine.\"\"<\/p>\n

August 11, 2020: <\/strong>Sputnik V gets regulatory approval.<\/p>\n

September 7, 2020: <\/strong>Gamaleya begins trial of Sputnik V.<\/p>\n

November 24, 2020: <\/strong>Trial result shows 95% efficacy.<\/p>\n

December 2, 2020: <\/strong>President Putin calls for mass vaccination with Sputnik V.<\/p>\n

 <\/p>\n

Sinopharm<\/strong><\/p>\n

Sinopharm\u2019s <\/strong>vaccine is a two-dose adenovirus-based vaccine that can be stored at 2\u20138 \u00baC. Its trial was done on 50,000 participants. The company is conducting late stage trials of two candidate vaccines.<\/p>\n

July 2020: <\/strong>Chinese company Sinopharm begins trial of its vaccine.\"\"<\/p>\n

August 28, 2020: <\/strong>Vaccine gets early approval for high risk groups in China.<\/p>\n

September 14, 2020: <\/strong>Emergency use approval for health workers granted in UAE.<\/p>\n

December 9, 2020: <\/strong>Trial result shows vaccine to be 86% effective.<\/p>\n

December 9, 2020: <\/strong>Vaccine gets full approval in UAE.<\/p>\n

December 13, 2020: <\/strong>Vaccine gets full approval in Bahrain.<\/p>\n

 <\/p>\n

Sinovac Biotech<\/strong><\/p>\n

Sinovac Biotech\u2019s <\/strong>vaccine (CoronaVac) is a two-dose vaccine that can be stored at 2\u20138 \u00baC. Its trial included 26,000 participants. The vaccine triggers an immune response u<\/p>\n

\"\"<\/p>\n

sing inactivated COVID-19 virus. The company plans to produce 600 million doses a year. Cost is $30 per dose.<\/p>\n

July 21, 2020: <\/strong>Chinese company Sinovac Biotech begins trial of its vaccine in Brazil, Indonesia, and Turkey.<\/p>\n

August 25, 2020: <\/strong>Deal signed with Indonesia to deliver 40 million doses.<\/p>\n

August 28, 2020: <\/strong>Vaccine gets early approval for high risk groups in China.<\/p>\n

November 9, 2020: <\/strong>Trial paused in Brazil due to an adverse event.<\/p>\n

November 11, 2020: <\/strong>Trial resumes again.<\/p>\n

 <\/p>\n

Moderna<\/strong><\/p>\n

Moderna <\/strong>is a two-dose mRNA vaccine that can be stored at 2-8 \u00baC. Its trial included 30,000 participants. The company aims to produce 20 million doses for the<\/p>\n

\"\"<\/p>\n

US in December 2020 and 100 million for global distribution in the next quarter. Cost is from $25-$37 per dose.<\/p>\n

July 27, 2020: <\/strong>US company Moderna begins trial of its vaccine.<\/p>\n

November 16, 2020: <\/strong>Trial result shows 94.5% efficacy.<\/p>\n

November 30, 2020: <\/strong>Company applies to FDA for emergency use authorization of its vaccine.<\/p>\n

December 18, 2020: <\/strong>Vaccine granted emergency use authorization in USA.<\/p>\n

 <\/p>\n

AstraZeneca-University of Oxford<\/strong><\/p>\n

\"\"<\/p>\n

AstraZeneca-Oxford<\/strong> vaccine is a two-dose adenovirus-based vaccine that can be stored at 2-8 \u00baC. The trial comprised of 65,000 participants. The company has received orders of 3 billion doses even before late-stage trial results. Cost is $3-$4 per dose.<\/p>\n

August 28, 2020: <\/strong>UK company AstraZeneca and University of Oxford begins trial of their vaccine.<\/p>\n

September 8, 2020: <\/strong>Trial paused due to safety concerns.<\/p>\n

October 23, 2020: <\/strong>Trial resumes again.<\/p>\n

November 23, 2020: <\/strong>Aggregated analysis of trial results shows 70% efficacy.<\/p>\n

December 7, 2020: <\/strong>Serum Institute of India applies for emergency use authorization for CoviShield, the name for AstraZeneca-Oxfords\u2019s vaccine produced by them in India.<\/p>\n

 <\/p>\n

Johnson & Johnson<\/strong><\/p>\n

Johnson & Johnson <\/strong>vaccine is a one-dose adenovirus-based vaccine that can be stored at 2-8 \u00baC. The trial comprised of 70,000 volunteers. The company aims to pr<\/p>\n

\"\"<\/p>\n

oduce one billion doses in 2021. Cost is $10 per dose.<\/p>\n

September 7, 2020: <\/strong>US company Johnson & Johnson begins trial of its vaccine.<\/p>\n

October 12, 2020: <\/strong>Trial paused to investigate adverse reaction in a volunteer.<\/p>\n

October 25, 2020: <\/strong>Trial resumes again.<\/p>\n

November 16, 2020: <\/strong>Company announces second trial with two doses.<\/p>\n

 <\/p>\n

Novavax<\/strong><\/p>\n

Novavax vaccine <\/strong>is a two-dose vaccine engineered from the genetic sequence of SARS-CoV-2 that can be stored at 2-8 \u00baC. Its trial included 45,000 participants. Cost<\/p>\n

\"\"<\/p>\n

is $16 per dose.<\/p>\n

September 15, 2020: <\/strong>US company Novavax announces agreement with Serum Institute of India to manufacture two billion doses of it vaccine candidate.<\/p>\n

September 28, 2020: <\/strong>Novavax begins trial of its vaccine in UK.<\/p>\n

 <\/p>\n

References:
\n1. Bloomberg, December 12, 2020, https:\/\/bloom.bg\/37dzWeL<\/a>
\n2. Healthline, November 29, 2020,
\n3. Biospace, November 24, 2020, <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

CanSino Biologics CanSino Biologics\u2019 vaccine is a one-dose adenovirus-based vaccine that can be stored at 2\u20138 \u00baC. Its trial included 40,000 volunteers. March 2020: China\u2019s CanSino Biologics and the Academy of Military Medical Sciences launch phase 1 trial in Wuhan after getting regulatory approval to start human trials of their vaccine against the novel coronavirus. …<\/p>\n","protected":false},"author":4,"featured_media":1934,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[273],"tags":[130,115,270,112],"class_list":["post-1924","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-timeline","tag-coronavirus","tag-covid-19","tag-trial","tag-vaccine"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/medicosnext.com\/wp-content\/uploads\/2021\/01\/Covid-19-Vaccine-development-e1599531596297.jpg?fit=1600%2C900&ssl=1","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/medicosnext.com\/index.php?rest_route=\/wp\/v2\/posts\/1924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicosnext.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicosnext.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicosnext.com\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicosnext.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1924"}],"version-history":[{"count":0,"href":"https:\/\/medicosnext.com\/index.php?rest_route=\/wp\/v2\/posts\/1924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicosnext.com\/index.php?rest_route=\/wp\/v2\/media\/1934"}],"wp:attachment":[{"href":"https:\/\/medicosnext.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicosnext.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicosnext.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}